Background: Epidemic Kaposi’s sarcoma is the most common AIDS-defining cancer especially in sub-Saharan Africa where HIV burden is high. The combination of ARVs and chemotherapy is now a cornerstone in the treatment of EKS. Despite the wide use of chemotherapy, there have been very few studies on the outcome of chemotherapy treatment. Objectives: To describe the outcome of chemotherapy treatment to patients with EKS at RDTC. Methodology: This is the cross sectional medical record review which was conducted at RDTC at KCMC using medical records of patients with EKS and who received treatments for EKS. Convenient sampling technique was used where by records of all patients who are HIV positive and histologically confirmed Kaposi’s sarcoma from 1st January 2011 to 31st December 2015 were included.Statistical analysis was done using the Statistical Package for Social Sciences (SPSS) program version 20.0. Results: About 54 patients with EKS on chemotherapy, 85.2% received Doxorubicin/Bleomycin/vincristine and 14.8% received bleomycin/vincristine. Treatment outcome were as follows; 9 (16.7%) had complete response, 31(57.4%) had partial response, 4(7.4%) had stable disease and 10(18.5) had progrogressive disease. Nausea and vomiting which occured in 6 patients was the most common side effect recorded followed by anemia, thrombocytopenia and fever which were each recorded once. Conclusion:This study shows that chemotherapy treatment (ABV or BV) has favourable tumor response and less myelotoxicity. These benefits coupled with their relative cheap availabity, make ABV or BV suitable in resource limited hospitals in sub-Saharan Africa like KCMC.